Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2021

Aug 31, 2021

30016_dirs_2021-08-31_36ace5ce-c892-4ea5-ba68-b97364eb455a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-08-27

Reporting Person: Turner Kathy V (Senior Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-27 Common Stock M 276 $64.24 Acquired 3151.3869 Direct
2021-08-27 Common Stock S 276 $678 Disposed 2875.3869 Direct
2021-08-30 Common Stock M 2250 $79.54 Acquired 5125.3869 Direct
2021-08-30 Common Stock S 1000 $685 Disposed 4125.3869 Direct
2021-08-30 Common Stock S 1250 $689 Disposed 2875.3869 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-27 Non-Qualified Stock Option (right-to-buy) $64.24 M 276 Disposed 2024-05-31 Common Stock (276) Direct
2021-08-30 Non-Qualified Stock Option (right-to-buy) $79.54 M 2250 Disposed 2025-05-13 Common Stock (2250) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 100 Indirect

Footnotes

F1: Includes a total of 9.3869 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2021.

F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.

F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 138 shares in five annual installments beginning June 1, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F4: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F5: Not applicable.